1370 related articles for article (PubMed ID: 22918931)
1. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.
Finn OJ
Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii6-9. PubMed ID: 22918931
[TBL] [Abstract][Full Text] [Related]
2. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer.
Jäger D; Jäger E; Knuth A
J Clin Pathol; 2001 Sep; 54(9):669-74. PubMed ID: 11533070
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
4. Challenges and future perspectives of T cell immunotherapy in cancer.
de Aquino MT; Malhotra A; Mishra MK; Shanker A
Immunol Lett; 2015 Aug; 166(2):117-33. PubMed ID: 26096822
[TBL] [Abstract][Full Text] [Related]
5. Genetically modified tumour vaccines--where we are today.
Nawrocki S; Mackiewicz A
Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy II: Antigens, receptors and costimulation.
Searle PF; Young LS
Cancer Metastasis Rev; 1996 Sep; 15(3):329-49. PubMed ID: 9034595
[TBL] [Abstract][Full Text] [Related]
7. Angiostasis as a way to improve immunotherapy.
Griffioen AW; Vyth-Dreese FA
Thromb Haemost; 2009 Jun; 101(6):1025-31. PubMed ID: 19492143
[TBL] [Abstract][Full Text] [Related]
8. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
9. Differentiation and Regulation of T
Basu A; Ramamoorthi G; Albert G; Gallen C; Beyer A; Snyder C; Koski G; Disis ML; Czerniecki BJ; Kodumudi K
Front Immunol; 2021; 12():669474. PubMed ID: 34012451
[TBL] [Abstract][Full Text] [Related]
10. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
12. The dawn of vaccines for cancer prevention.
Finn OJ
Nat Rev Immunol; 2018 Mar; 18(3):183-194. PubMed ID: 29279613
[TBL] [Abstract][Full Text] [Related]
13. Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy.
Dredge K; Marriott JB; Todryk SM; Dalgleish AG
Cancer Immunol Immunother; 2002 Nov; 51(10):521-31. PubMed ID: 12384803
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of EBV inducing anti-tumour immunity and its therapeutic use.
Choi IK; Wang Z; Ke Q; Hong M; Paul DW; Fernandes SM; Hu Z; Stevens J; Guleria I; Kim HJ; Cantor H; Wucherpfennig KW; Brown JR; Ritz J; Zhang B
Nature; 2021 Feb; 590(7844):157-162. PubMed ID: 33361812
[TBL] [Abstract][Full Text] [Related]
15. Tumor rejection antigens and tumor specific cytotoxic T lymphocytes.
Toes RE; Offringa R; Feltkamp MC; Visseren MJ; Schoenberger SP; Melief CJ; Kast WM
Behring Inst Mitt; 1994 Jul; (94):72-86. PubMed ID: 7998917
[TBL] [Abstract][Full Text] [Related]
16. Specific immunotherapy of cancer in elderly patients.
Matzku S; Zöller M
Drugs Aging; 2001; 18(9):639-64. PubMed ID: 11599633
[TBL] [Abstract][Full Text] [Related]
17. Combination cancer immunotherapy and new immunomodulatory targets.
Mahoney KM; Rennert PD; Freeman GJ
Nat Rev Drug Discov; 2015 Aug; 14(8):561-84. PubMed ID: 26228759
[TBL] [Abstract][Full Text] [Related]
18. Tuning cancer fate: the unremitting role of host immunity.
Calì B; Molon B; Viola A
Open Biol; 2017 Apr; 7(4):. PubMed ID: 28404796
[TBL] [Abstract][Full Text] [Related]
19. Combination cancer immunotherapies tailored to the tumour microenvironment.
Smyth MJ; Ngiow SF; Ribas A; Teng MW
Nat Rev Clin Oncol; 2016 Mar; 13(3):143-58. PubMed ID: 26598942
[TBL] [Abstract][Full Text] [Related]
20. Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies.
Marr LA; Gilham DE; Campbell JD; Fraser AR
Clin Exp Immunol; 2012 Feb; 167(2):216-25. PubMed ID: 22235997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
